NanOlogy, LLC, a clinical-stage oncology company, announced that results from its Phase 1/2 clinical trial of SOR007 in the treatment of cutaneous metastases were presented during the 2020 San Antonio Breast Cancer Symposium by Mario Lacouture, MD, Director of Oncodermatology, Memorial Sloan Kettering Cancer Center.
December 29, 2020
· 4 min read